Infectious Disease · Opportunistic Infections
The facts most likely to be tested
Pneumocystis jirovecii pneumonia (PJP) is the most common AIDS-defining opportunistic infection in patients with a CD4 count < 200 cells/µL.
Patients typically present with an insidious onset of progressive exertional dyspnea, non-productive cough, and low-grade fever.
Classic chest X-ray findings include bilateral diffuse interstitial infiltrates, though imaging may be normal in early disease.
Arterial blood gas analysis frequently reveals hypoxemia with an increased alveolar-arterial (A-a) oxygen gradient.
The diagnostic gold standard is the identification of organisms via methenamine silver stain or direct fluorescent antibody (DFA) testing of induced sputum or bronchoalveolar lavage (BAL) fluid.
First-line treatment for PJP is trimethoprim-sulfamethoxazole (TMP-SMX), with the addition of adjunctive corticosteroids if the PaO2 is < 70 mmHg or the A-a gradient is ≥ 35 mmHg.
Prophylaxis with TMP-SMX is indicated for all HIV-positive patients with a CD4 count < 200 cells/µL or a history of oropharyngeal candidiasis.
Vignette unlocked
A 34-year-old male with a history of untreated HIV presents to the clinic with a 3-week history of progressive shortness of breath and a dry, hacking cough. He reports a 10-lb weight loss and night sweats. On physical exam, he is afebrile, but his oxygen saturation is 91% on room air. Lung auscultation is clear to percussion and auscultation. A chest X-ray shows bilateral perihilar interstitial opacities. His CD4 count is 85 cells/µL.
What is the most appropriate initial pharmacologic management for this patient's respiratory condition?
Trimethoprim-sulfamethoxazole and systemic corticosteroids
The patient has PJP, evidenced by the low CD4 count and classic radiographic findings; because his hypoxemia indicates a significant A-a gradient, adjunctive steroids are required to prevent respiratory failure.
Full handout
High yield triage
Etiology / Epidemiology
Opportunistic fungal infection in HIV/AIDS patients with CD4 count <200 cells/µL.
Clinical Manifestations
Progressive exertional dyspnea, non-productive cough, and ground-glass opacities on imaging.
Diagnosis
Bronchoalveolar lavage (BAL) with silver stain is the gold standard for definitive diagnosis.
Treatment
Trimethoprim-sulfamethoxazole (TMP-SMX) is first-line; add prednisone if PaO2 <70 mmHg.
Prognosis
High mortality if untreated; prophylaxis required until CD4 >200 for 3 months.
Full handout
Epidemiology & Etiology
Caused by the fungus Pneumocystis jirovecii, primarily affecting immunocompromised hosts. The most significant risk factor is HIV/AIDS with a CD4 count <200 cells/µL. Other populations include patients on chronic corticosteroids, transplant recipients, or those on immunosuppressive chemotherapy.
Pertinent Anatomy
The organism primarily targets the alveolar spaces, leading to diffuse interstitial inflammation. This impairs gas exchange at the alveolar-capillary membrane, resulting in profound hypoxemia.
Pathophysiology
Inhaled cysts attach to alveolar type I pneumocytes, triggering a massive inflammatory response. This leads to the accumulation of proteinaceous, foamy exudate within the alveoli. The resulting ventilation-perfusion mismatch causes progressive hypoxemia and elevated A-a gradient.
Clinical Manifestations
Patients present with an insidious onset of exertional dyspnea, fever, and a non-productive cough. Physical exam is often unremarkable despite severe hypoxia, a classic dissociation between clinical findings and severity. Red flags include rapid respiratory failure and cyanosis. Imaging reveals bilateral, symmetric ground-glass opacities.
Diagnosis
The gold standard is identification of organisms via bronchoalveolar lavage (BAL) using methenamine silver stain. Serum beta-D-glucan is a sensitive but non-specific marker. Arterial blood gas typically shows an A-a gradient >35 mmHg in symptomatic patients.
Treatment
Trimethoprim-sulfamethoxazole (TMP-SMX) is the first-line treatment. If the patient is hypoxic with PaO2 <70 mmHg or A-a gradient >35 mmHg, adjunctive prednisone must be started to prevent respiratory failure. Contraindications for TMP-SMX include severe sulfa allergy; use pentamidine or atovaquone as alternatives.
Prognosis
Untreated cases carry a high mortality rate due to respiratory failure. Key complications include spontaneous pneumothorax and persistent pulmonary fibrosis. Patients require prophylaxis with TMP-SMX until CD4 counts remain above 200 cells/µL for at least 3 months.
Differential Diagnosis
Bacterial pneumonia: usually lobar consolidation on CXR
Tuberculosis: cavitary lesions and night sweats
Cytomegalovirus pneumonia: usually occurs with other end-organ disease
Histoplasmosis: associated with bird/bat droppings and endemic geography
Pulmonary edema: associated with elevated BNP and cardiac history